U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Both Ozempic and Wegovy are forms of semaglutide, a GLP-1 agonist drug manufactured by Novo Nordisk. When reached for comment ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

There are two ways to be eligible for a Wegovy prescription: Have a BMI of 30 or higher Have a BMI of 27 or higher and a ...

Learn more about who is eligible and what to expect at your initial appointment. Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist, was first approved by the Food and Drug ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...